A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...